论文部分内容阅读
本文收集腹腔镜或手术证实为子宫内膜异位症Ⅲ、Ⅳ期患者45例,随机分成三组,分别应用丹那唑、他莫西芬和丹那唑加他莫西芬联合治疗。随访临床治疗效果并测定外周血淋巴细胞(PBL)中IL—2诱生水平和 T 细胞亚群分析。结果表明,丹那唑联合他莫西芬治疗效果好,副作用少,优于单独应用丹那唑或他莫西芬治疗。子宫内膜异位症患者 PBL 中 IL—2诱生水平和 CD_4~+/CD_~+值明显高于对照组(P<0.01);丹那唑、他莫西芬治疗后 IL—2诱生水平和 CD_4~+/CD_~+值明显下降(P<0.01).说明子宫内膜异位症患者体内有细胞免疫功能和平衡状态的异常,丹那唑和他莫西芬有免疫抑制作用。
This collection of laparoscopic or surgical confirmed endometriosis in patients with stage Ⅲ, Ⅳ 45 patients were randomly divided into three groups, respectively, the application of danazol, tamoxifen and danazol plus tamoxifen combined treatment. Clinical outcomes were followed up and IL-2 induced levels and T-cell subsets were analyzed in peripheral blood lymphocytes (PBLs). The results showed that danazol combined with tamoxifen effect is good, less side effects, better than the single use of danazol or tamoxifen treatment. The level of IL-2 and the level of CD_4 ~ + / CD_ ~ + in PBL of patients with endometriosis were significantly higher than those of the control group (P <0.01). The levels of IL-2 induced by danazol and tamoxifen And CD_4 ~ + / CD_ ~ + values were significantly decreased (P <0.01), indicating that patients with endometriosis have abnormal cellular immune function and balance status, and that danazol and tamoxifen have immunosuppressive effects.